The emergence of Zika virus in the Americas has caused an increase of babies born with microcephaly or other neurological malformations. The differential diagnosis of Zika infection, particularly serological diagnosis, is an important but complex issue. In this study, Nearly all the IgM, and 92% of immunoglobulin G positive results were confirmed by neutralization test. Zika specific neutralizing antibodies were detected in as much as 90.4% of the cases. Moreover, dengue specific neutralizing antibodies were detected in 79.0% of Zika seropositive mothers. In conclusion, Zika IgM negative results should be considered with caution, due to a possible rapid loss of sensitivity after birth, while the NS1-based Zika IgM enzyme-linked immunosorbent assay test we have used has demonstrated to be highly specific. In a high percentage of cases, Zika specific neutralizing antibodies were detected, which are indicative of a past Zika infection, probably occurred during pregnancy in this population.
ZIKV outbreaks occurred, such as those in Micronesia and French Polynesia. 2 In March, 2015, autochthonous virus transmission was first detected in Brazil. 3 ZIKV has since then rapidly spread throughout South and Central America, and the Caribbean. These regions had already been interested, in the last decades, by a dramatic increase in dengue virus (DENV) circulation, with the simultaneous co-circulation of the four serotypes in several areas, and also by the emergence of other arboviruses, such as West Nile and chikungunya virus (CHIKV). [4] [5] [6] Illness resulting from ZIKV infection is typically mild and selflimiting. The majority (approximately 80%) of ZIKV infections have been estimated to be asymptomatic. 2 However, since 2013, an increased incidence of neurological symptoms following ZIKV acute infection, including the Guillain Barré syndrome, has been reported. 7 Furthermore, the emergence of ZIKV in the Americas coincided with increased reports of babies born with microcephaly and brain and ocular malformations. [8] [9] [10] [11] [12] [13] The causal association was acknowledged by the World Health Organization (WHO) 14 and by the US Centers for Disease Control and Prevention in April, 2016, 15 and further supported by accumulating evidence. 10, 11, [16] [17] [18] [19] [20] [21] Differential diagnosis of ZIKV infection, particularly the diagnosis of congenital ZIKV infection, as well as the screening of pregnant women for detection of ZIKV infection, are important but complex issues. 22 Molecular detection of the virus is the golden standard for differential diagnosis, but it is limited by the short or variable persistence of the virus in different biological fluids both of the mother and the fetus. 10, [23] [24] [25] [26] Serological diagnosis of ZIKV infection is challenging, mainly due to the high cross-reactivity between flaviviruses. [27] [28] [29] It includes an initial screening for anti-ZIKV immunoglobulin M (IgM), followed by confirmation using a neutralization test, the standard serological assay for distinguishing between different flaviviruses. NS1-based enzyme-linked immunosorbent assay (ELISA) IgM tests have demonstrated to be highly specific, 30 but their sensitivity might be limited among ZIKV infected patients with past flavivirus infections. 31, 32 Moreover, while neutralization tests are highly specific in case of primary flavivirus infection, secondary flavivirus infections often stimulate the original antigenic sin phenomenon, leading to significant neutralizing antibody cross-reactivity between closely related flaviviruses. 26, 33 However, it is not known whether these crossreactive neutralizing antibodies are durable. Notably, pre-existing immunity to DENV might enhance infection with ZIKV, leading to increased disease severity, with possible implications also for the risk of development of fetal disease. [34] [35] [36] [37] The main aim of the present work is to describe the results of serological tests performed on serum samples collected from children with a suspected congenital ZIKV infection and/or from their mothers. Overall, we have analyzed 94 suspected cases of congenital ZIKV infection from Bahia state, an area which has been heavily affected by the ZIKV epidemic. 38, 39 Clinical manifestations, together with bioimaging findings, are also described.
| MATERIALS AND METHODS

| Studied population and samples
In this study, the cases (n = 94) were recruited among children 3 | RESULTS
| Serological assays
| Epidemiological and clinical features
All the patients lived in Bahia, Brazil. 
| Serological laboratory findings in mothers and children
The results of ZIKV ELISA IgM and IgG tests, and PRNTs for ZIKV, DENV, and CHIKV in mothers and children serum samples are shown in 51 Conversely, the percentage of ZIKV IgM positive results among children (7.1%) in our study is much lower than the 27.0% of positivity reported by de Araújo et al, 12 and 90.5% reported by Cordeiro et al. 51 We think it is unlikely that this difference is due to 12,51
The specificity of serological tests in the context of co-circulation of different arboviruses is still a matter of discussion. 26, 33 The main limitation of our study is the lack of a control population (healthy children, matched by date of delivery, and area of residence), so that definitive conclusions cannot be drawn from our laboratory data.
However, the prevalence of ZIKV-specific IgG and neutralizing antibodies in our population was comparable to those reported among mothers of neonates born with microcephaly in the same area and in the same period. 12, 52 The high DENV seroprevalence we have observed, and the lower prevalence for CHIKV compared to DENV and ZIKV, are also comparable with data available from the literature. [52] [53] [54] Finally, in agreement with other evidence, 30 With respect to the specificity of neutralization tests, ZIKV crossreactive neutralizing antibodies induced by DENV infection have been reported not to be durable, 55 suggesting that neutralization tests for ZIKV should be sufficiently specific in late convalescent-phase sera.
Efforts to define ZIKV neutralization tests cut off able to distinguish past ZIKV infections from immunity to previous flavivirus infections, as well as toward the standardization of PRNTs, are needed.
Overall, PRNT seems to be from our data the more sensitive and specific test for the diagnosis of past ZIKV infection, even if it cannot be used to determine timing of infection. At the moment, the presence in mothers and/or in children samples of ZIKV-specific neutralizing antibodies should be interpreted, in our opinion, as a possible ZIKV infection during pregnancy.
In this population, a high percentage of ZIKV PRNT positive mothers were also DENV PRNT positive (79.0%). Whether a previous DENV immunity may represent an additional risk factor for the development of ZIKV infection associated congenital syndrome is another important matter of discussion: however, again, only the analysis of a control population (mothers of healthy children), and also DENV and other arboviruses seroprevalence studies in areas of ZIKV circulation, will allow to draw conclusions from our and others' data.
While the possibility of some infants without apparent clinical findings at birth, but who may have complications from congenital ZIKV infection, has been documented, 56 guidance for testing and case definition for children visited not immediately after birth are not yet defined. 57, 58 Although ZIKV-specific neutralizing antibody titers have been shown to be significantly higher in mothers of children with microcephaly than in mothers of children born without microcephaly, suggesting the potential utility of maternal antibody titers to corroborate congenital ZIKV infection, 43 an absolute titer threshold suggestive of congenital infection has not been indicated.
In conclusion, the evidence of congenital infection in a large proportion of cases of suspected ZIKV-associated malformations cannot be definitely proved. Our data confirm the difficulty of an accurate retrospective diagnosis of ZIKV congenital infection and the urgent need of further evaluation of available serological tests, as well as the development of innovative tools.
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